| 1 |
Development of new compounds for effective gene editing therapy for an IMPDH1 mutation causing autosomal dominant retinitis pigmentosa |
| Gene Therapy |
Retinitis Pigmentosa |
IMPDH1 |
Hit |
Ulsan University |
RS-2023-00283544 |
|
| 2 |
Development of AAV based ocular cell/tissue targeting technology and treatment candidates for the development of gene therapy for X.chromosome.linked retinitis pigmentosa |
| Gene Therapy |
Retinitis Pigmentosa |
RPGR |
Hit |
ENCell |
RS-2023-00258840 |
|
| 3 |
Retinal regenerative antibody and gene therapy |
| Antibody |
Degenerative Retinal Disease |
PROX1 |
Hit |
CELLIAZ |
RS-2023-00258166 |
|
| 4 |
Lead identification for retinal diseases using selective NO delivery compounds |
| Small Molecules |
Retinal vein occlusion |
Co, Fe |
Hit |
Ulsan National Institute of Science & Technology |
RS-2023-00217242 |
|
| 5 |
Development of gene therapeutics targeting EYS-related Retinitis Pigmentosa |
| Recombinant Protein |
Retinitis pigmentosa |
EYS c.4957dupA |
Hit |
Sungkyunkwan University |
HN22C0571 |
|
| 6 |
Development of novel gene therapy for PDE6B related inherited retinal disease |
| Gene Therapy |
Genetic Retinal disease |
PDE6B |
Hit |
Asan Medical Center |
HN22C0245 |
|
| 7 |
To develop the lead of a new oral drug for age-related macular degeneration |
| Small Molecules |
Age-related macular degeneration |
PDK4 |
Hit |
Kyungpook National University |
HN21C0923 |
|
| 8 |
Lead generation of prime editor for genetic variants of Leber congenital amaurosis |
| Gene Therapy |
Leber Congenital Amaurosis |
CEP290 |
Hit |
Seoul National University |
HN21C0917 |
|
| 9 |
Lead development of orally available drug for diabetic retinopathy targeting TGase 2 to inhibit vascular leakage |
| Small Molecules |
Diabetic retinopathy |
TGase2 |
Hit |
Daegu Gyyeongbuk Medical Innovation Foundation |
HN21C1155 |
|
| 10 |
Development of recombinant protein targeting human complement C5 for dry age.related macular degeneration treatment |
| Antibody |
Macular degeneration |
Human Complement C5 |
Lead |
Immunabs Co., Ltd. |
RS-2023-00282906 |
|
| 11 |
Development of lead compound for Leber hereditary optic neuropathy |
| Small Molecules |
Leber hereditary optic neuropathy |
NQO1 |
Lead |
Curome Bioscience |
RS-2023-00259507 |
|
| 12 |
Discovery of first-in-Class AMD treatment for dry eye using Autophagy activation |
| Small Molecules |
Dry macular degeneration |
Autophage |
Lead |
VasThera |
RS-2022-00166507 |
|
| 13 |
Development of therapeutic candidate: Tie2 and Ang2 dual modulator for the next.generation treatment of wAMD and DR. |
| Antibody |
wet AMD/DR |
Ang2.targeting Tie2 receptor |
Candidate |
Neortesbio Co.,Ltd. |
RS-2023-00282960 |
|
| 14 |
Development of First.in.Class mutant transcript.selective ASO therapeutic candidates for the treatment of Avellino corneal dystrophy |
| Gene Therapy |
Avellino corneal dystrophy |
Human TGFBIR124H |
Candidate |
MediciBIO Co., LTD |
RS-2023-00282731 |
|
| 15 |
Recombinant human HAPLN1 protein: a multi-functional therapeutic candidate to treat dry eye disease |
| Recombinant Protein |
Dry eye disease |
HAPLN1 |
Candidate |
HaplnScience Inc. |
RS-2023-00217306 |
|
| 16 |
Discovery of Non-clinical Development Candidate Molecule for a Novel Universal Retinitis Pigmentosa Therapeutics |
| Gene Therapy |
Retinitis Pigmentosa |
RORβ |
Candidate |
OliX Pharmaceuticals |
RS-2023-00217014 |
|
| 17 |
Nonclinical drug candidates targeting TRAP1 to treat diabetic retinopathy |
| Small Molecules |
Diabetic retinopathy |
TRAP1 |
Candidate |
SMARTIN BIO Inc. |
HN21C0882 |
|
